The National Cancer Institute (NCI) established the Office of HIV and AIDS Malignancy (OHAM) in December 2007 to enhance its research effort in the field of HIV/AIDS and HIV malignancies. Its Director is Dr. Robert Yarchoan.
The NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic, and scientists within and supported by the NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the Divisions and Offices of the NCI. In the years prior to 2007, this research was coordinated by the AIDS Malignancy Program, which resided in the Division of Cancer Treatment and Diagnosis (DCTD). However, HIV/AIDS and HIV malignancy research takes place throughout the NCI, and its coordination will be facilitated by creation of OHAM and its location in the Office of the Director.OHAM was created to:
- Enhance HIV/AIDS research within and supported by the NCI
- Facilitate NCI-wide coordination and prioritization of this effort
- Manage certain HIV/AIDS-specific research activities
- Act as a point of contact with the NIH Office of AIDS Research (OAR) and other Institutes and Centers
OHAM includes two Programs:
- The AIDS Malignancy Program
Led by Dr. Kishor Bhatia, the AIDS Malignancy Program (AMP) has the primary responsibility for identifying new initiatives, for international activities, such as the initiative to Strengthen Capacity for HIV-Associated Malignancy Research in Africa, and for overseeing programs that the NCI co-manages with other Institutes, such as the Centers for AIDS Research (CFARs), the Multicenter AIDS Cohort Study (MACS), and the Women's Interagency HIV Study.
- The AIDS Cancer Clinical Program
Led by Dr. Mostafa Nokta, the AIDS Cancer Clinical Program (ACCP) has the primary responsibility for overseeing clinical programs in OHAM, including the AIDS Malignancy Consortium (AMC) and the AIDS and Cancer Specimen Resource (ACSR).
Learn more about the research programs and activities of OHAM.